Wedbush Weighs in on AnaptysBio’s Q1 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Wedbush boosted their Q1 2026 EPS estimates for shares of AnaptysBio in a research report issued on Monday, November 10th. Wedbush analyst M. Fan now forecasts that the biotechnology company will post earnings per share of ($0.78) for the quarter, up from their previous estimate of ($0.88). Wedbush currently has a “Outperform” rating and a $50.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Wedbush also issued estimates for AnaptysBio’s Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($2.83) EPS, FY2027 earnings at ($1.66) EPS, FY2028 earnings at ($0.63) EPS and FY2029 earnings at $0.73 EPS.

A number of other brokerages have also issued reports on ANAB. Barclays decreased their price target on AnaptysBio from $83.00 to $70.00 and set an “overweight” rating for the company in a research note on Tuesday. Wells Fargo & Company lifted their target price on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. HC Wainwright lowered their target price on shares of AnaptysBio from $59.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday. JPMorgan Chase & Co. upped their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Finally, Truist Financial raised their price target on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio has a consensus rating of “Moderate Buy” and an average price target of $59.40.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $33.26 on Wednesday. The firm has a market capitalization of $920.97 million, a PE ratio of -11.79 and a beta of 0.16. The business has a 50 day simple moving average of $29.80 and a two-hundred day simple moving average of $25.03. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $40.96.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. The company had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%.

Hedge Funds Weigh In On AnaptysBio

Several institutional investors have recently made changes to their positions in ANAB. First Light Asset Management LLC boosted its stake in shares of AnaptysBio by 433.3% during the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock valued at $86,139,000 after purchasing an additional 3,764,720 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in AnaptysBio by 4,852.7% during the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after buying an additional 822,975 shares during the period. Caption Management LLC boosted its position in AnaptysBio by 106.3% during the 1st quarter. Caption Management LLC now owns 23,376 shares of the biotechnology company’s stock valued at $435,000 after acquiring an additional 394,634 shares in the last quarter. Woodline Partners LP increased its holdings in shares of AnaptysBio by 63.1% in the 1st quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock valued at $14,705,000 after acquiring an additional 305,950 shares during the period. Finally, 683 Capital Management LLC raised its position in shares of AnaptysBio by 155.6% in the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after acquiring an additional 304,373 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.